Biosimilar

Improving Accessibility and Affordability of Existing Biological Drugs

Prestige Biopharma is committed to advancing biosimilars to ensure sustainable, safe,
and affordable biologic medicines worldwide.

15

Biosimilar Pipelines

Pipeline

INN

Trade Name

Indiaction

Development Stage

TUZNUE

Trastuzumab

Herceptin

Oncology

EU Approved (Sep 2024)

TUZNUE Learn more

9

VASFORDA

Bevacizumab

Avastin

Oncology

BLA Preparation

VASFORDA Learn more

9

PBP1502

Adalimumab

Humira

Immunology

Phase 1

PBP1502 Learn more

9

PBP1601

Denosumab

Prolia

Bone Disorders

IND Preparation

PBP2101

Nivolumab

Opdivo

Oncology

IND Preparation

PBP2102

Pembrolizumab

Keytruda

Oncology

IND Preparation

IDC2301

Emicizumab

Hemlibra

Hematology

Discovery

IDC2401

Ustekinumab

Stelara

Immunology

Discovery

IDC2402

Dulaglutide

Trulicity

Endocrinology

Discovery

IDC2403

Ocrelizumab

Ocrevus

Immunology

Discovery

IDC2404

Vedolizumab

Entyvio

Immunology

Discovery

IDC2405

Pertuzumab

Perjeta

Oncology

Discovery

IDC2501

Dupilumab

Dupixent

Dermatology

Discovery

IDC2502

Risankizumab

Skyrizi

Immunology

Discovery

IDC2503

Atezolizumab

Tecentriq

Oncology

Discovery

Pipelines

TUZNUE
INN / Originator Therapeutic Area
Trastuzumab /
Herceptin		 Oncology
Development Stage
Approved (EU)
TUZNUE Learn more >>

Pipelines

VASFORDA
INN / Originator Therapeutic Area
Bevacizumab / Avastin Oncology
Development Stage
BLA Preparation
VASFORDA Learn more >>

Pipelines

PBP1502
INN / Originator Therapeutic Area
Adalimumab /
Humira		 Immunology
Development Stage
Phase I
PBP1502 Learn more >>

Pipelines

PBP1601
INN / Originator Therapeutic Area
Denosumab /
Prolia		 Endocrinology
Development Stage
IND preparation

Pipelines

PBP2101
INN / Originator Therapeutic Area
Nivolumab /
Opdivo		 Oncology
Development Stage
Discovery

Pipelines

PBP2102
INN / Originator Therapeutic Area
Pembrolizumab / Keytruda Oncology
Development Stage
Discovery

Pipelines

IDC2301
INN / Originator Therapeutic Area
Emicizumab /
Hemlibra		 Hematology
Development Stage
Discovery

Pipelines

IDC2401
INN / Originator Therapeutic Area
Ustekinumab /
Stelara		 Immunology
Development Stage
Discovery

Pipelines

IDC2402
INN / Originator Therapeutic Area
Dulaglutide /
Trulicity		 Endocrinology
Development Stage
Discovery

Pipelines

IDC2403
INN / Originator Therapeutic Area
Ocrelizumab / Ocrevus Immunology
Development Stage
Discovery

Pipelines

IDC2404
INN / Originator Therapeutic Area
Vedolizumab /
Entyvio		 Immunology
Development Stage
Discovery

Pipelines

IDC2405
INN / Originator Therapeutic Area
Pertuzumab /
Perjeta		 Oncology
Development Stage
Discovery

Pipelines

IDC2501
INN / Originator Therapeutic Area
Dupilumab /
Dupixent		 Dermatology
Development Stage
Discovery

Pipelines

IDC2502
INN / Originator Therapeutic Area
Risankizumab / Skyrizi Immunology
Development Stage
Discovery

Pipelines

IDC2503
INN / Originator Therapeutic Area
Atezolizumab /
Tecentriq		 Oncology
Development Stage
Discovery